{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:40:48Z","timestamp":1780929648659,"version":"3.54.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.maturitas.2021.06.014","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T11:00:30Z","timestamp":1625310030000},"page":"36-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Hyperprolactinemia after menopause: Diagnosis and management"],"prefix":"10.1016","volume":"151","author":[{"given":"Renata S.","family":"Auriemma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Pirchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.maturitas.2021.06.014_bib0001","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.beem.2009.05.003","article-title":"Pituitary tumours: the prolactinoma","volume":"23","author":"Colao","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.maturitas.2021.06.014_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.maturitas.2021.06.014_bib0003","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.maturitas.2021.06.014_bib0004","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1210\/jc.2007-2677","article-title":"24-hour serum levels of growth hormone, prolactin, and cortisol in pre- and postmenopausal women: the effect of combined estrogen and progestin treatment","volume":"93","author":"Kalleinen","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12020-017-1438-7","article-title":"Prolactinoma through the female life cycle","volume":"59","author":"Cocks Eschler","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0006","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000494725","article-title":"Hyperprolactinemia\/Prolactinomas in the Postmenopausal Period: challenges in Diagnosis and Management","volume":"109","author":"Peki\u0107","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0007","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11102-019-00998-0","article-title":"Prolactinomas and menopause: any changes in management?","volume":"23","author":"Greenman","year":"2020","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.maturitas.2021.06.014_bib0008","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrendo.2011.37","article-title":"Medical treatment of prolactinomas","volume":"7","author":"Colao","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9","key":"10.1016\/j.maturitas.2021.06.014_bib0009","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJM198608283150903","article-title":"Increase in bone mass after treatment of hyperprolactinemic amenorrhea","volume":"315","author":"Klibanski","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.maturitas.2021.06.014_bib0010","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","article-title":"Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea","volume":"64","author":"Schlechte","year":"1987","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2021.06.014_bib0011","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fendo.2019.00327","article-title":"Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas","volume":"10","author":"Auriemma","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"10.1016\/j.maturitas.2021.06.014_bib0012","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0015-0282(97)81368-4","article-title":"Hyperprolactinemia in postmenopausal women","volume":"67","author":"Maor","year":"1997","journal-title":"Fertil. Steril."},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0013","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12020-014-0259-1","article-title":"Women with prolactinomas presented at the postmenopausal period","volume":"47","author":"Shimon","year":"2014","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.maturitas.2021.06.014_bib0014","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cen.13399","article-title":"Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes","volume":"87","author":"Santharam","year":"2017","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"5","key":"10.1016\/j.maturitas.2021.06.014_bib0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr. Rev."},{"issue":"7","key":"10.1016\/j.maturitas.2021.06.014_bib0016","first-page":"2102","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study","volume":"82","author":"Delgrange","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0017","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000499382","article-title":"Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours","volume":"109","author":"Trouillas","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.maturitas.2021.06.014_bib0018","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1210\/jcem-66-4-868","article-title":"Pathological hyperprolactinemia suppresses hot flashes in menopausal women","volume":"66","author":"Scoccia","year":"1988","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.maturitas.2021.06.014_bib0019","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/cen.12204","article-title":"Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels","volume":"79","author":"Ciresi","year":"2013","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"4","key":"10.1016\/j.maturitas.2021.06.014_bib0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000357810","article-title":"Effect of cabergoline on metabolism in prolactinomas","volume":"98","author":"Auriemma","year":"2013","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.maturitas.2021.06.014_bib0021","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17446651.2018.1434412","article-title":"The effects of hyperprolactinemia and its control on metabolic diseases","volume":"13","author":"Auriemma","year":"2018","journal-title":"Expert Rev. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0022","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/HYPERTENSIONAHA.109.132100","article-title":"Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors","volume":"54","author":"Georgiopoulos","year":"2009","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.maturitas.2021.06.014_bib0023","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/jhh.2017.15","article-title":"Prolactin as a predictor of endothelial dysfunction and arterial stiffness progression in menopause","volume":"31","author":"Georgiopoulos","year":"2017","journal-title":"J. Hum. Hypertens."},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0024","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0008-6363(00)00005-5","article-title":"The roles of gender, the menopause and hormone replacement on cardiovascular function","volume":"46","author":"Hayward","year":"2000","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/157489009789152249","article-title":"Gender differences in ischemic heart disease","volume":"4","author":"Wake","year":"2009","journal-title":"Recent Pat. Cardiovasc. Drug Discov."},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0026","doi-asserted-by":"crossref","first-page":"20631","DOI":"10.1038\/s41598-020-77534-9","article-title":"A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0027","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bone.2007.11.008","article-title":"Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand\/osteoprotegerin ratio","volume":"42","author":"Seriwatanachai","year":"2008","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.maturitas.2021.06.014_bib0028","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jcb.22161","article-title":"Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization","volume":"107","author":"Seriwatanachai","year":"2009","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.maturitas.2021.06.014_bib0029","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11102-011-0293-4","article-title":"High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas","volume":"14","author":"Mazziotti","year":"2011","journal-title":"Pituitary"},{"issue":"9","key":"10.1016\/j.maturitas.2021.06.014_bib0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJM198608283150903","article-title":"Increase in bone mass after treatment of hyperprolactinemic amenorrhea","volume":"315","author":"Klibanski","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.maturitas.2021.06.014_bib0031","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1210\/jcem-56-6-1120","article-title":"Bone density in amenorrheic women with and without hyperprolactinemia","volume":"56","author":"Schlechte","year":"1983","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.maturitas.2021.06.014_bib0032","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","article-title":"Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea","volume":"64","author":"Schlechte","year":"1987","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0033","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1210\/jcem-67-1-124","article-title":"Effects of prolactin and estrogen deficiency in amenorrheic bone loss","volume":"67","author":"Klibanski","year":"1988","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.maturitas.2021.06.014_bib0034","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11102-008-0097-3","article-title":"The effects of hyperprolactinemia on bone and fat","volume":"12","author":"Shibli-Rahhal","year":"2009","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0035","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s11102-020-01041-3","article-title":"Hyperprolactinemia and bone","volume":"23","author":"di Filippo","year":"2020","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.maturitas.2021.06.014_bib0036","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1517\/14740338.2016.1151493","article-title":"The safety of treatments for prolactinomas","volume":"15","author":"Auriemma","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.maturitas.2021.06.014_bib0037","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6823-10-10","article-title":"Cushing\u2019s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas","volume":"10","author":"Biller","year":"2010","journal-title":"BMC Endocr. Disord."},{"issue":"2","key":"10.1016\/j.maturitas.2021.06.014_bib0038","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11154-008-9107-z","article-title":"Medical therapy of pituitary adenomas: effects on tumor shrinkage","volume":"10","author":"Colao","year":"2009","journal-title":"Rev. Endocr. Metab. Disor."},{"issue":"5","key":"10.1016\/j.maturitas.2021.06.014_bib0039","first-page":"557","article-title":"Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels","volume":"129","author":"Reyes","year":"1977","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.maturitas.2021.06.014_bib0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/09513599709152546","article-title":"Changes in prolactin levels with the menopause: the effects of estrogen\/androgen and calcitonin treatment","volume":"11","author":"Balint-Peri\u0107","year":"1997","journal-title":"Gynecol. Endocrinol."},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0041","first-page":"761","article-title":"Prolactin pulsatile characteristics in postmenopausal women","volume":"83","author":"Katznelson","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0042","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of the menopause on prolactin levels in patients with hyperprolactinaemia","volume":"54","author":"Karunakaran","year":"2001","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0043","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1590\/2359-3997000000138","article-title":"Prolactinomas: evolution after menopause","volume":"60","author":"Mallea-Gil","year":"2016","journal-title":"Arch. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0044","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/cen.13765","article-title":"Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal","volume":"89","author":"Santharam","year":"2018","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"2\u20133","key":"10.1016\/j.maturitas.2021.06.014_bib0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12672-019-00363-4","article-title":"Cabergoline Withdrawal Before and After Menopause: outcomes in Microprolactinomas","volume":"10","author":"Indirli","year":"2019","journal-title":"Horm. Cancer"},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0046","first-page":"337","article-title":"Influence of pregnancies on prolactinomas","volume":"100","author":"Rjosk","year":"1982","journal-title":"Acta Endocrinol. (Copenh)"},{"issue":"40","key":"10.1016\/j.maturitas.2021.06.014_bib0047","first-page":"2117","article-title":"La grossesse: une modalit\u00e9 de gu\u00e9rison des ad\u00e9nomes \u00e0 prolactine? Dix-huit observations [Pregnancy: a way of recovering from prolactin-secreting adenoma? 18 cases]","volume":"17","author":"Bricaire","year":"1988","journal-title":"Presse Med."},{"issue":"8","key":"10.1016\/j.maturitas.2021.06.014_bib0048","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/oxfordjournals.humrep.a137010","article-title":"Is pregnancy the best treatment for hyperprolactinaemia?","volume":"4","author":"Crosignani","year":"1989","journal-title":"Hum. Reprod."},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0049","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0028-2243(92)90094-F","article-title":"Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women","volume":"44","author":"Crosignani","year":"1992","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0050","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","article-title":"Long-term follow-up of patients with hyperprolactinaemia","volume":"45","author":"Jeffcoate","year":"1996","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"4","key":"10.1016\/j.maturitas.2021.06.014_bib0051","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2265.2009.03657.x","article-title":"Factors determining the remission of microprolactinomas after dopamine agonist withdrawal","volume":"72","author":"Huda","year":"2010","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0052","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1210\/jc.2012-3039","article-title":"Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation","volume":"98","author":"Auriemma","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.maturitas.2021.06.014_bib0053","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12370","article-title":"Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients","volume":"80","author":"Domingue","year":"2014","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"10","key":"10.1016\/j.maturitas.2021.06.014_bib0054","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1055\/s-0043-112861","article-title":"Pregnancy and Tumor Outcomes in Women with Prolactinoma","volume":"125","author":"Araujo","year":"2017","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/ajo.13070","article-title":"An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists","volume":"60","author":"O\u2019Sullivan","year":"2020","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"issue":"2","key":"10.1016\/j.maturitas.2021.06.014_bib0056","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11102-019-01008-z","article-title":"A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas","volume":"23","author":"Sant\u2019 Anna","year":"2020","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0057","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12020-014-0308-9","article-title":"The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons","volume":"48","author":"Faje","year":"2015","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0058","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0015-0282(16)55819-1","article-title":"The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia","volume":"59","author":"Corenblum","year":"1993","journal-title":"Fertil. Steril."},{"issue":"2","key":"10.1016\/j.maturitas.2021.06.014_bib0059","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0010-7824(98)00069-9","article-title":"Two-year treatment with oral contraceptives in hyperprolactinemic patients","volume":"58","author":"Testa","year":"1998","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/09513599209015553","article-title":"The effect of combined estrogen\/progestogen treatment in women with hyperprolactinemic amenorrhea","volume":"6","author":"Fahy","year":"1992","journal-title":"Gynecol. Endocrinol."},{"issue":"4","key":"10.1016\/j.maturitas.2021.06.014_bib0061","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11102-012-0450-4","article-title":"Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas","volume":"16","author":"Mon","year":"2013","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0062","first-page":"499","article-title":"Levels of prolactin in relation to coagulation factors and risk of venous thrombosis. Results of a large population-based case-control study (MEGA-study)","volume":"108","author":"Stuijver","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.maturitas.2021.06.014_bib0063","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/BF02554932","article-title":"Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia","volume":"37","author":"Caraceni","year":"1985","journal-title":"Calcif. Tissue Int."},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0064","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2265.2000.00902.x","article-title":"Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization","volume":"52","author":"Colao","year":"2000","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"7","key":"10.1016\/j.maturitas.2021.06.014_bib0065","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-110-7-526","article-title":"Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism","volume":"110","author":"Greenspan","year":"1989","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.maturitas.2021.06.014_bib0066","first-page":"996","article-title":"Osteopenia in women with hypothalamic amenorrhea: a prospective study","volume":"78","author":"Biller","year":"1991","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.maturitas.2021.06.014_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2001-0036","article-title":"The role of prolactin in mammary carcinoma","volume":"24","author":"Clevenger","year":"2003","journal-title":"Endocr. Rev."},{"issue":"15","key":"10.1016\/j.maturitas.2021.06.014_bib0068","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/0008-5472.CAN-13-0665","article-title":"A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development","volume":"73","author":"Tworoger","year":"2013","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.maturitas.2021.06.014_bib0069","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11102-009-0214-y","article-title":"The risk for breast cancer is not evidently increased in women with hyperprolactinemia","volume":"13","author":"Mm Dekkers","year":"2010","journal-title":"Pituitary"},{"issue":"8","key":"10.1016\/j.maturitas.2021.06.014_bib0070","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1530\/EC-17-0171","article-title":"Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study","volume":"6","author":"Soto-Pedre","year":"2017","journal-title":"Endocr. Connect."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512221001183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512221001183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:18:23Z","timestamp":1759915103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512221001183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":70,"alternative-id":["S0378512221001183"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2021.06.014","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperprolactinemia after menopause: Diagnosis and management","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2021.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}